Search Results 461-470 of 11393 for anti-TNF drugs

  1. mRNA transfection improves CTL response in immunotherapy - Mayo Clinic

    ... treatment with anti-PD-1 and anti-PD-L1 at Mayo Clinic. Outcomes of treatment were evaluated using standard clinical practice guidelines and the Response ...

  2. Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, And Nivolumab In Treating Patients With Stage I-II Hodgkin Lymphoma - Mayo Clinic

    Requires therapy with agents ... agents, corticosteroids or immunosuppressive drugs). ... Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

  3. CAR-T cell therapy - Mayo Clinic

    It also helps minimize anti-CAR reactions from your immune system. Lymphodepleting chemotherapy is usually an outpatient procedure unless hospitalization is ...

  4. Inflammation May Play a Role in Irritable Bowel Syndrome

    ... anti-inflammatory medications in controlling IBS symptoms hasn't shown any benefit. As a result, anti-inflammatory drugs are not generally used to treat IBS.

  5. A Study To Assess The Effectiveness And Safety Of Pacritinib In Patients With VEXAS Syndrome (PAXIS) - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic Health ... Anti-TNFα agents except for etanercept (e.g., infliximab): 60 days.

  6. A Placebo-Controlled Study Of Oral Ozanimod As Maintenance Therapy For Moderately To Severely Active Crohn's Disease - Mayo Clinic

    Subject has received treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with 2 or more agents in combination known to prolong PR interval.

  7. Safety And Efficacy Of ALLO-605 An Anti-BCMA Allogeneic CAR T Cell Therapy In Patients With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Safety And Efficacy Of ALLO-605 An Anti-BCMA Allogeneic CAR T Cell Therapy In Patients With Relapsed/Refractory Multiple Myeloma. Print details. Share; Facebook ...

  8. Major advance in use of CAR-T cell therapy to treat solid tumors - Mayo Clinic

    Researchers at Mayo Clinic have made a promising breakthrough in the development of a novel therapy for solid tumor treatment. Hong Qin, M.D., Ph.D., ...

  9. Myeloid Cell Interactions Modulate Combination Immunotherapy Outcomes in the Liver Tumor Microenvironment - Mayo Clinic Research

    We have conducted preliminary studies of combination anti-PD-1 and anti-PD-L1 ICI treatment on B16 tumors. Once inoculated, tumors rapidly grew logarithmically ...

  10. Non Clinical Trials - Mayo Clinic Research

    Rituximab, an anti-CD20 chimeric antibody, was approved by the United States Food and Drug Administration in 1998 for the treatment of patients with relapsed ...